Other News To Note
Convergence Pharmaceuticals Ltd., of Cambridge, UK, initiated a Phase II proof-of-concept study of CNV1014802 in pain associated with trigeminal neuralgia (TN). CNV1014802 is a small-molecule, state-dependent sodium channel blocker that exhibits potency and selectivity against the Nav1.7 sodium channel.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST